Nuveen
NAGE

Nuveen’s Niagen Bioscience NAGE Stock Holding History

Nuveen’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429K Buy
134,606
+11,336
+9% +$46K ﹤0.01% 3341
2026
Q1 		$544K Sell
123,270
-368,692
-75% -$1.99M ﹤0.01% 2806
2025
Q4 		$3.13M Sell
491,962
-298,943
-38% -$2.08M ﹤0.01% 2109
2025
Q3 		$7.38M Sell
790,905
-114,581
-13% -$1.16M ﹤0.01% 1717
2025
Q2 		$13M Buy
905,486
+839,372
+1,270% +$8.29M ﹤0.01% 1341
2025
Q1 		$456K Hold
66,114
– – ﹤0.01% 2932
2024
Q4 		$351K Hold
66,114
– – ﹤0.01% 3091
2024
Q3 		$241K Hold
66,114
– – ﹤0.01% 3187
2024
Q2 		$180K Buy
+66,114
New +$221K ﹤0.01% 3235
2022
Q2 		– Sell
-762,027
Closed -$1.88M – 3520
2022
Q1 		$1.88M Sell
762,027
-17,941
-2% -$49K ﹤0.01% 2533
2021
Q4 		$3.13M Sell
779,968
-2,036
-0.3% -$11K ﹤0.01% 2356
2021
Q3 		$5.29M Buy
782,004
+418,085
+115% +$3.45M ﹤0.01% 2177
2021
Q2 		$3.59M Buy
363,919
+207,036
+132% +$1.81M ﹤0.01% 2412
2021
Q1 		$1.47M Buy
156,883
+15,134
+11% +$120K ﹤0.01% 2753
2020
Q4 		$681K Buy
141,749
+2,152
+2% +$10.5K ﹤0.01% 2937
2020
Q3 		$560K Buy
139,597
+749
+0.5% +$3.61K ﹤0.01% 2917
2020
Q2 		$637K Buy
138,848
+29,849
+27% +$134K ﹤0.01% 2808
2020
Q1 		$356K Sell
108,999
-96
-0.1% -$369 ﹤0.01% 2888
2019
Q4 		$470K Sell
109,095
-1,960
-2% -$6.97K ﹤0.01% 2917
2019
Q3 		$437K Buy
111,055
+12,267
+12% +$52.3K ﹤0.01% 2985
2019
Q2 		$460K Buy
+98,788
New +$421K ﹤0.01% 3033

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nuveen's NAGE Position: Q2 2026 in Review

Nuveen increased its Niagen Bioscience (NAGE) stake by 9.2% in Q2 2026, buying an estimated $46K and bringing the position to 134,606 shares worth $429K. The position accounts for ﹤0.01% of the portfolio, ranked #3341.

Nuveen first reported a position in NAGE in Q2 2019 and has held it in 21 quarters since. The position peaked at $13M in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Nuveen held 134,606 shares of Niagen Bioscience worth $429K as of Q2 2026.
  • Nuveen bought 11,336 Niagen Bioscience shares in Q2 2026, an estimated $46K.
  • Niagen Bioscience made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3341 holding.
  • Nuveen first reported a position in Niagen Bioscience in Q2 2019 and has held it in 21 quarters since.
  • Nuveen's Niagen Bioscience position peaked at $13M in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.